Transformation of indolent B-cell lymphomas

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1827-1834

  Montoto, Silvia ^a   Fitzgibbon, Jude ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; LENALIDOMIDE; PREDNISONE; PROCARBAZINE; PURINE DERIVATIVE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; RISK FACTORS;

EID: 79955814702     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.7577     Document Type: Review

References (73)

1. Cullen MH, Lister TA, Brearley RI, et al: Histological transformation of non-Hodgkin's lymphoma: A prospective study. Cancer 44:645-651, 1979 (Pubitemid 10220149)
2. Hubbard SM, Chabner BA, DeVita VT Jr, et al: Histologic progression in non-Hodgkin's lymphoma. Blood 59:258-264, 1982 (Pubitemid 12172012)
3. Acker B, Hoppe RT, Colby TV, et al: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11-16, 1983 (Pubitemid 13066136)
4. Ersboll J, Schultz HB, Pedersen-Bjergaard J, et al: Follicular low-grade non-Hodgkin's lymphoma: Long-term outcome with or without tumor progression. Eur J Haematol 42:155-163, 1989 (Pubitemid 19064945)
5. Yuen AR, Kamel OW, Halpern J, et al: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726-1733, 1995
6. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997 (Pubitemid 27167397)
7. Gine E, Montoto S, Bosch F, et al: The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545, 2006 (Pubitemid 44542041)
8. Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433, 2007 (Pubitemid 47007616)
9. Al-Tourah AJ, Gill KK, Chhanabhai M, et al: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26:5165-5169, 2008
10. Morley NJ, Evans LS, Goepel J, et al: Transformed follicular lymphoma: The 25-year experience of a UK provincial lymphoma treatment centre. Oncol Rep 20:953-956, 2008
11. Richter MN: Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 4:285-292, 1928
12. Tsimberidou AM, O'Brien S, Khouri I, et al: Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343-2351, 2006 (Pubitemid 46655600)
13. Rossi D, Cerri M, Capello D, et al: Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 142:202-215, 2008 (Pubitemid 351987315)
14. Tsimberidou AM, O'Brien S, Kantarjian HM, et al: Hodgkin transformation of chronic lymphocytic leukemia: The M. D. Anderson Cancer Center experience. Cancer 107:1294-1302, 2006
15. Lin P, Mansoor A, Bueso-Ramos C, et al: Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: Clinicopathologic features of 12 cases. Am J Clin Pathol 120:246-253, 2003 (Pubitemid 37046359)
16. Yoshino T, Omonishi K, Kobayashi K, et al: Clinicopathological features of gastric mucosa associated lymphoid tissue (MALT) lymphomas: High grade transformation and comparison with diffuse large B cell lymphomas without MALT lymphoma features. J Clin Pathol 53:187-190, 2000 (Pubitemid 30163600)
17. Hiyama T, Haruma K, Kitadai Y, et al: Clinicopathological features of gastric mucosa-associated lymphoid tissue lymphoma: A comparison with diffuse large B-cell lymphoma without a mucosa-associated lymphoid tissue lymphoma component. J Gastroenterol Hepatol 16:734-739, 2001 (Pubitemid 34188809)
18. Ferreri AJ, Freschi M, Dell'Oro S, et al: Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-cell gastric lymphomas. Am J Surg Pathol 25:95-102, 2001 (Pubitemid 32001838)
19. Nakamura S, Matsumoto T, Iida M, et al: Primary gastrointestinal lymphoma in Japan: A clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 97:2462-2473, 2003 (Pubitemid 36542485)
20. Biasoli I, Stamatoullas A, Meignin V, et al: Nodular, lymphocyte-predominant Hodgkin lymphoma: A long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631-639, 2010
21. Al-Mansour M, Connors JM, Gascoyne RD, et al: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 2010
22. Al-Tourah AJ, Savage KJ, Gill KK, et al: Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. American Society of Hematology, Annual Meeting, Atlanta, GA, 2007
23. Tan D, Rosenberg SA, Lavori P, et al: Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003. 10th International Conference on Malignant lymphoma, Lugano, Switzerland, 2008, pp iv111
24. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984 (Pubitemid 15211022)
25. Bernstein SH, Burack WR: The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 532-541, 2009
26. Schoder H, Noy A, Gonen M, et al: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651, 2005 (Pubitemid 46224066)
27. Noy A, Schoder H, Gonen M, et al: The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 20:508-512, 2009
28. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al: Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47: 1267-1273, 2006 (Pubitemid 47544878)
29. Bodet-Milin C, Kraeber-Bodere F, Moreau P, et al: Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 93:471-472, 2008 (Pubitemid 351398655)
30. Foran JM, Apostolidis J, Papamichael D, et al: High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre. Ann Oncol 9:865-869, 1998 (Pubitemid 28440445)
31. Risdall R, Hoppe RT, Warnke R: Non-Hodgkin's lymphoma: A study of the evolution of the disease based upon 92 autopsied cases. Cancer 44:529-542, 1979 (Pubitemid 10220137)
32. Garvin AJ, Simon RM, Osborne CK, et al: An autopsy study of histologic progression in non- Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer 52:393-398, 1983 (Pubitemid 13073462)
33. Pescarmona E, Pignoloni P, Mauro FR, et al: Hodgkin/Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: An immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Virchows Arch 437:129-132, 2000 (Pubitemid 30623571)
34. Nakamura N, Kuze T, Hashimoto Y, et al: Analysis of the immunoglobulin heavy chain gene of secondary diffuse large B-cell lymphoma that sub-sequently developed in four cases with B-cell chronic lymphocytic leukemia or lymphoplasmacytoid lymphoma (Richter syndrome). Pathol Int 50: 636-643, 2000
35. Mao Z, Quintanilla-Martinez L, Raffeld M, et al: IgVH mutational status and clonality analysis of Richter's transformation: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 31:1605-1614, 2007 (Pubitemid 47482476)
36. Relander T, Johnson NA, Farinha P, et al: Prognostic factors in follicular lymphoma. J Clin Oncol 28:2902-2913, 2010
37. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004 (Pubitemid 39507628)
38. Glas AM, Kersten MJ, Delahaye LJ, et al: Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105:301-307, 2005 (Pubitemid 40053097)
39. Gentles AJ, Alizadeh AA, Lee SI, et al: A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood 114:3158-3166, 2009
40. O'Riain C, O'Shea DM, Yang Y, et al: Array-based DNA methylation profiling in follicular lymphoma. Leukemia 23:1858-1866, 2009
41. Martin-Subero JI, Kreuz M, Bibikova M, et al: New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113:2488-2497, 2009
42. Matolcsy A, Schattner EJ, Knowles DM, et al: Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol 29: 1253-1264, 1999 (Pubitemid 29164172)
43. Carlotti E, Wrench D, Matthews J, et al: Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 113:3553-3557, 2009
44. Ruminy P, Jardin F, Picquenot JM, et al: S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: Early direct or late from FL progenitor cells. Blood 112:1951-1959, 2008
45. d'Amore F, Chan E, Iqbal J, et al: Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res 14:7180-7187, 2008
46. Eide MB, Liestol K, Lingjaerde OC, et al: Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116:1489-1497, 2010
47. Fitzgibbon J, Iqbal S, Davies A, et al: Genomewide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia 21:1514-1520, 2007 (Pubitemid 46965294)
48. Johnson NA, Al-Tourah A, Brown CJ, et al: Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes Cancer 47:1038-1048, 2008
49. Agopian J, Navarro JM, Gac AC, et al: Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 206:1473-1483, 2009
50. Roulland S, Navarro JM, Grenot P, et al: Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 203:2425-2431, 2006 (Pubitemid 44664612)
51. Irish JM, Myklebust JH, Alizadeh AA, et al: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107:12747-12754, 2010
52. Irish JM, Czerwinski DK, Nolan GP, et al: Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108:3135-3142, 2006
53. Morin RD, Johnson NA, Severson TM, et al: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185, 2010
54. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997 (Pubitemid 27106296)
55. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
56. Lepage E, Sebban C, Gisselbrecht C, et al: Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial. Hematol Oncol 8:31-39, 1990 (Pubitemid 20087128)
57. Thornton PD, Bellas C, Santon A, et al: Richter's transformation of chronic lymphocytic leukemia: The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 29:389-395, 2005 (Pubitemid 40255812)
58. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009
59. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
60. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
61. Fisher DE, Jacobson JO, Ault KA, et al: Diffuse large cell lymphoma with discordant bone marrow histology: Clinical features and biological implications. Cancer 64:1879-1887, 1989
62. Robertson LE, Redman JR, Butler JJ, et al: Discordant bone marrow involvement in diffuse large-cell lymphoma: A distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 9:236-242, 1991
63. Chung R, Lai R, Wei P, et al: Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 110:1278-1282, 2007 (Pubitemid 47281426)
64. Sehn LH, Chhanabhai M, Singh S, et al: Both discordant and concordant bone marrow (BM) involvement predict for a poorer outcome independent of the IPI in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. American Society of Hematology, Annual Meeting, Atlanta, GA, 2007
65. Ghesquieres H, Berger F, Felman P, et al: Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 24:5234-5241, 2006 (Pubitemid 46631367)
66. Hans CP, Weisenburger DD, Vose JM, et al: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003 (Pubitemid 36302082)
67. Koch P, Probst A, Berdel WE, et al: Treatment results in localized primary gastric lymphoma: Data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23:7050-7059, 2005
68. Williams CD, Harrison CN, Lister TA, et al: High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19:727-735, 2001 (Pubitemid 32119087)
69. Rezvani AR, Storer B, Maris M, et al: Nonmy-eloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26:211-217, 2008
70. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
71. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
72. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000 (Pubitemid 30159851)
73. Reeder CB, Vose J, Witzig TE, et al: Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003). J Clin Oncol 2010 28:582s (suppl; abstr 8037)